Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Trial Profile

Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Uteroglobin (Primary)
  • Indications Asthma; Bronchopulmonary dysplasia; Cough; Respiratory distress syndrome; Respiratory tract infections; Wheezing
  • Focus Therapeutic Use
  • Sponsors Therabron Therapeutics
  • Most Recent Events

    • 11 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 11 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018.
    • 12 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top